See more : Artemis Resources Limited (ARV.L) Income Statement Analysis – Financial Results
Complete financial analysis of TerrAscend Corp. (TRSSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TerrAscend Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nissui Pharmaceutical Co., Ltd. (4550.T) Income Statement Analysis – Financial Results
- DD3 Acquisition Corp. II (DDMX) Income Statement Analysis – Financial Results
- Hermès International Société en commandite par actions (HMI.DE) Income Statement Analysis – Financial Results
- Petra Acquisition, Inc. (PAIC) Income Statement Analysis – Financial Results
- Lewis & Clark Bancorp (LWCL) Income Statement Analysis – Financial Results
TerrAscend Corp. (TRSSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.terrascend.com
About TerrAscend Corp.
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania. In addition, it owns various synergistic under Gage Cannabis, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. brands. As of July 26, 2022, the company operated 27 dispensaries, including 3 Cookies dispensaries in Michigan and 1 in Toronto. TerrAscend Corp. was incorporated in 2017 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 317.33M | 322.64M | 243.49M | 198.32M | 84.87M | 6.83M | 0.00 | 0.00 |
| Cost of Revenue | 157.63M | 203.07M | 109.38M | 171.98M | 87.52M | 10.17M | 381.32K | 0.00 |
| Gross Profit | 159.70M | 119.57M | 134.11M | 26.34M | -2.65M | -3.34M | -381.32K | 0.00 |
| Gross Profit Ratio | 50.33% | 37.06% | 55.08% | 13.28% | -3.12% | -48.96% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 426.00K | 709.00K | 141.00K | 0.00 | 0.00 |
| General & Administrative | 100.35M | 101.22M | 71.85M | 57.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.66M | 10.32M | 1.86M | 1.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 110.01M | 150.48M | 94.16M | 75.17M | 61.68M | 24.67M | 6.27M | 866.94K |
| Other Expenses | 72.69M | 206.00K | 230.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 182.69M | 150.48M | 94.16M | 75.60M | 62.39M | 24.81M | 6.27M | 866.94K |
| Cost & Expenses | 340.32M | 353.55M | 203.54M | 247.58M | 149.91M | 34.98M | 6.66M | 866.94K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 640.18K | 36.28K | 9.00 |
| Interest Expense | 35.11M | 39.06M | 24.99M | 7.03M | 4.09M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.70M | 32.03M | 17.38M | 16.57M | 7.32M | 921.00K | 244.08K | 0.00 |
| EBITDA | -1.03M | -320.94M | 104.54M | -96.45M | -204.22M | -20.52M | -6.56M | -866.94K |
| EBITDA Ratio | -0.32% | 0.35% | 23.54% | -16.48% | -68.01% | -398.97% | 0.00% | 0.00% |
| Operating Income | -23.00M | -30.91M | 39.95M | -49.26M | -65.04M | -28.16M | -6.66M | -866.94K |
| Operating Income Ratio | -7.25% | -9.58% | 16.41% | -24.84% | -76.63% | -412.47% | 0.00% | 0.00% |
| Total Other Income/Expenses | -35.84M | -279.28M | 15.88M | -77.21M | -152.29M | 6.72M | -149.23K | -244.00 |
| Income Before Tax | -58.83M | -403.82M | 55.83M | -126.47M | -217.33M | -21.44M | -6.81M | -867.18K |
| Income Before Tax Ratio | -18.54% | -125.16% | 22.93% | -63.77% | -256.08% | -314.09% | 0.00% | 0.00% |
| Income Tax Expense | 23.45M | -14.04M | 36.20M | 27.87M | 1.62M | 704.00K | -3.00 | 0.00 |
| Net Income | -91.10M | -429.49M | 3.90M | -155.12M | -215.79M | -22.03M | -6.81M | -867.18K |
| Net Income Ratio | -28.71% | -133.12% | 1.60% | -78.22% | -254.26% | -322.71% | 0.00% | 0.00% |
| EPS | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
| EPS Diluted | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
| Weighted Avg Shares Out | 279.29M | 244.35M | 181.06M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
| Weighted Avg Shares Out (Dil) | 279.29M | 244.35M | 208.71M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
TerrAscend Corp. (TRSSF) Management on Q2 2022 Results Earnings Call Transcript
Top Marijuana Stocks Right Now? 2 US Pots Stocks To Watch
3 Marijuana Stocks To Watch To End The Week
2 Pot Stocks For Your 2022 Investment Portfolio
Are US Marijuana Stocks A Buy Before August 2022?
Top Marijuana Penny Stocks For Your Mid-July Watchlist
3 Cannabis Companies To Buy In The Stock Market Today?
TerrAscend Turns Its First Profit as Revenues Rise
3 Marijuana Stocks For Your July Watchlist
An Introduction To TerrAscend: A Wild Opportunity
Source: https://incomestatements.info
Category: Stock Reports